Phaseline

Targets › CLDN6

CLDN6 (Claudin-6): drug programs, companies and trials

5 programs from 4 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Jan 2027.

Plays a major role in tight junction-specific obliteration of the intercellular space..; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) entry into hepatic cells. (UniProt, P56747)

Open in Phaseline: the race on CLDN6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovaRock BiotherapeuticsNBL-028
anti-CLDN6 antibody-drug conjugate
CLDN6Phase 1Advanced Solid TumorJan 2027
BeOne MedicinesBGB-B455
anti-CLDN6 antibody-drug conjugate
CLDN6Phase 1Advanced Solid TumorApr 2028
Context TherapeuticsCTIM-76
CLDN6-directed T cell-engaging bispecific antibody
CLDN6Phase 1Platinum-resistant Ovarian CancerMay 2028
BioNTech Cell & Gene TherapiesCLDN6 CAR-T
CAR-T cell therapy targeting CLDN6
CLDN6Phase 1Solid TumorAug 2028
BioNTech Cell & Gene TherapiesCLDN6 uRNA-LPX/CLDN6 modRNA-LPX
RNA-based vaccine targeting CLDN6
CLDN6Phase 1Solid TumorAug 2028

Conditions

Solid Tumor (2) Advanced Solid Tumor (2) Platinum-resistant Ovarian Cancer (1)

Modalities

mixed (2), small molecule (2), antibody (1)

Companies

BioNTech Cell & Gene Therapies (2) Context Therapeutics (1) BeOne Medicines (1) NovaRock Biotherapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.